Description
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Various developments in the biopharma industry are discussed, including Novo's CEO being pressured to cut prices of obesity and diabetes drugs, the FTC suing major pharmacy benefit managers over insulin prices, Bluebird laying off another 25% of its workforce, and Apellis' eye drug being turned down in Europe. Large pharmaceutical companies face challenges as paten...
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Merck has committed up to $3 billion in a deal with Lanova Medicines focused on PD-1/VEGF. The deal comes as Merck faces competition from Bristol Myers Squibb in...
Published 11/15/24
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Amgen's obesity candidate, maritide, faced new safety concerns related to bone density, causing a drop in the company's stock. Biogen's shares have also plummeted due to...
Published 11/14/24